GlassScriptPhysician profile
Maribeth C Chong
NPI 1932134756
$8,839.80
in general payments reported to CMS, 2019-2025
38 companies · $1,347 in 2025
The $1,347 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,056 · 2020: $951 · 2021: $938 · 2022: $1,641 · 2023: $2,197 · 2024: $710 · 2025: $1,347.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,163 · Travel and Lodging: $1,091.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,163.32 |
| Travel and Lodging | $1,090.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,546.21 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $1,176.97 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Alnylam Pharmaceuticals INC. | $675.62 | 2022 | |
| Amgen INC. | $611.75 | 2019-2023 | Prolia, Evenity |
| Novo Nordisk INC | $502.90 | 2019-2025 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $340.62 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Sanofi-Aventis U.S. LLC | $286.44 | 2019-2021 | |
| Lilly USA, LLC | $279.80 | 2020-2025 | Mounjaro, Jardiance, Zepbound |
| Allergan, INC. | $227.22 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $220.34 | 2019-2025 | Spravato |
| Pfizer INC. | $219.33 | 2019-2025 | |
| Idorsia Pharmaceuticals US INC | $191.36 | 2023-2024 | Quviviq |
| Abbott Laboratories | $166.40 | 2021-2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $140.28 | 2019-2024 | Xifaxan |
| Exact Sciences Corporation | $114.22 | 2023-2025 | Cologuard Collection Kit |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $101.41 | 2022-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Astellas Pharma US INC | $96.83 | 2019-2023 | Myrbetriq |
| Upsher-Smith Laboratories LLC | $95.98 | 2020 | |
| Radius Health, INC. | $87.67 | 2020-2023 | |
| Boston Scientific Corporation | $85.84 | 2024-2025 | Wavewriter Alpha Prime 16, Watchman Flx |
| Merck Sharp & Dohme LLC | $80.53 | 2019-2021 | |
| Indivior INC. | $71.86 | 2019 | |
| Dexcom, INC. | $67.34 | 2024-2025 | Dexcom G6 Transmitter |
| Gilead Sciences, INC. | $63.33 | 2025 | |
| Ultragenyx Pharmaceutical INC. | $57.95 | 2020-2021 | |
| Amarin Pharma, INC. | $42.23 | 2020-2021 | |
| Vivus LLC | $41.52 | 2021-2023 | Qsymia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.81 | 2023-2025 | Jardiance, Tradjenta |
| Eisai INC. | $35.94 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $33.69 | 2021 | |
| Antares Pharma, INC. | $23.72 | 2019 | |
| Hologic Sales and Service, LLC | $22.74 | 2023 | Aptima, Thinprep 2000 Processor |
| Nevro Corp. | $19.11 | 2022 | |
| Zyla Life Sciences, INC. | $17.30 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.39 | 2019 | |
| Tactile Systems Technology INC | $13.91 | 2021 | |
| Intra-Sana Laboratories | $13.63 | 2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Therapeuticsmd, INC. | $11.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maribeth Chong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.